107 related articles for article (PubMed ID: 35613100)
1. Trends in social exposure to SARS-Cov-2 in France. Evidence from the national socio-epidemiological cohort-EPICOV.
Warszawski J; Meyer L; Franck JE; Rahib D; Lydié N; Gosselin A; Counil E; Kreling R; Novelli S; Slama R; Raynaud P; Bagein G; Costemalle V; Sillard P; Fourie T; de Lamballerie X; Bajos N;
PLoS One; 2022; 17(5):e0267725. PubMed ID: 35613100
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of SARS-Cov-2 antibodies and living conditions: the French national random population-based EPICOV cohort.
Warszawski J; Beaumont AL; Seng R; de Lamballerie X; Rahib D; Lydié N; Slama R; Durrleman S; Raynaud P; Sillard P; Beck F; Meyer L; Bajos N;
BMC Infect Dis; 2022 Jan; 22(1):41. PubMed ID: 35000580
[TBL] [Abstract][Full Text] [Related]
3. Antibody status and cumulative incidence of SARS-CoV-2 infection among adults in three regions of France following the first lockdown and associated risk factors: a multicohort study.
Carrat F; de Lamballerie X; Rahib D; Blanché H; Lapidus N; Artaud F; Kab S; Renuy A; Szabo de Edelenyi F; Meyer L; Lydié N; Charles MA; Ancel PY; Jusot F; Rouquette A; Priet S; Saba Villarroel PM; Fourié T; Lusivika-Nzinga C; Nicol J; Legot S; Druesne-Pecollo N; Esseddik Y; Lai C; Gagliolo JM; Deleuze JF; Bajos N; Severi G; Touvier M; Zins M;
Int J Epidemiol; 2021 Nov; 50(5):1458-1472. PubMed ID: 34293141
[TBL] [Abstract][Full Text] [Related]
4. A Cross-Sectional Study of Exposure Factors Associated with Seropositivity for SARS-CoV-2 Antibodies during the Second Epidemic Wave among a Sample of the University of Corsica (France).
Decarreaux D; Sevila J; Masse S; Capai L; Fourié T; Saba Villarroel PM; Amroun A; Nurtop E; Vareille M; Pouquet M; Blanchon T; de Lamballerie X; Charrel R; Falchi A
Int J Environ Res Public Health; 2022 Feb; 19(4):. PubMed ID: 35206161
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household serosurvey.
Murhekar MV; Bhatnagar T; Selvaraju S; Saravanakumar V; Thangaraj JWV; Shah N; Kumar MS; Rade K; Sabarinathan R; Asthana S; Balachandar R; Bangar SD; Bansal AK; Bhat J; Chopra V; Das D; Deb AK; Devi KR; Dwivedi GR; Khan SMS; Kumar CPG; Kumar MS; Laxmaiah A; Madhukar M; Mahapatra A; Mohanty SS; Rangaraju C; Turuk A; Baradwaj DK; Chahal AS; Debnath F; Haq I; Kalliath A; Kanungo S; Kshatri JS; Lakshmi GGJN; Mitra A; Nirmala AR; Prasad GV; Qurieshi MA; Sahay S; Sangwan RK; Sekar K; Shukla VK; Singh PK; Singh P; Singh R; Varma DS; Viramgami A; Panda S; Reddy DCS; Bhargava B;
Lancet Glob Health; 2021 Mar; 9(3):e257-e266. PubMed ID: 33515512
[TBL] [Abstract][Full Text] [Related]
6. Seroprevalence of anti-SARS-CoV-2 antibodies after the first wave of the COVID-19 pandemic in a vulnerable population in France: a cross-sectional study.
Beaumont A; Durand C; Ledrans M; Schwoebel V; Noel H; Le Strat Y; Diulius D; Colombain L; Médus M; Gueudet P; Mouly D; Aumaître H
BMJ Open; 2021 Nov; 11(11):e053201. PubMed ID: 34815286
[TBL] [Abstract][Full Text] [Related]
7. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in the staff of a public school system in the midwestern United States.
Lopez L; Nguyen T; Weber G; Kleimola K; Bereda M; Liu Y; Accorsi EK; Skates SJ; Santa Maria JP; Smith KR; Kalinich M
PLoS One; 2021; 16(6):e0243676. PubMed ID: 34111144
[TBL] [Abstract][Full Text] [Related]
8. Seroprevalence of Unidentified SARS-CoV-2 Infection in Hong Kong During 3 Pandemic Waves.
Boon SS; Wong MCS; Ng RWY; Leung DTM; Chen Z; Lai CKC; Ho WCS; Huang J; Wong BKC; Fung KSC; Chan PKS
JAMA Netw Open; 2021 Nov; 4(11):e2132923. PubMed ID: 34779848
[TBL] [Abstract][Full Text] [Related]
9. Seroprevalence of SARS-CoV-2, Symptom Profiles and Sero-Neutralization in a Suburban Area, France.
Gégout Petit A; Jeulin H; Legrand K; Jay N; Bochnakian A; Vallois P; Schvoerer E; Guillemin F
Viruses; 2021 Jun; 13(6):. PubMed ID: 34200070
[TBL] [Abstract][Full Text] [Related]
10. Seroprevalence of SARS-CoV-2 Antibodies Among Children in School and Day Care in Montreal, Canada.
Zinszer K; McKinnon B; Bourque N; Pierce L; Saucier A; Otis A; Cheriet I; Papenburg J; Hamelin MÈ; Charland K; Carbonneau J; Zahreddine M; Savard A; Fortin G; Apostolatos A; Haley N; Ratté N; Laurin I; Nguyen CT; Conrod P; Boivin G; De Serres G; Quach C
JAMA Netw Open; 2021 Nov; 4(11):e2135975. PubMed ID: 34812845
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 transmission among children and staff in daycare centres during a nationwide lockdown in France: a cross-sectional, multicentre, seroprevalence study.
Lachassinne E; de Pontual L; Caseris M; Lorrot M; Guilluy C; Naud A; Dommergues MA; Pinquier D; Wannepain E; Hausherr E; Jung C; Gajdos V; Cohen R; Zahar JR; Brichler S; Basmaci R; Boelle PY; Bloch-Queyrat C; Aupiais C;
Lancet Child Adolesc Health; 2021 Apr; 5(4):256-264. PubMed ID: 33571450
[TBL] [Abstract][Full Text] [Related]
12. Seroprevalence of SARS-CoV-2 IgG Antibodies and Factors Associated with SARS-CoV-2 IgG Neutralizing Activity among Primary Health Care Workers 6 Months after Vaccination Rollout in France.
Decarreaux D; Pouquet M; Souty C; Vilcu AM; Prévot-Monsacre P; Fourié T; Villarroel PMS; Priet S; Blanché H; Sebaoun JM; Deleuze JF; Turbelin C; Werner A; Kochert F; Grosgogeat B; Rabiega P; Laupie J; Abraham N; Guerrisi C; Noël H; Van der Werf S; Carrat F; Hanslik T; Charrel R; De Lamballerie X; Blanchon T; Falchi A
Viruses; 2022 May; 14(5):. PubMed ID: 35632699
[TBL] [Abstract][Full Text] [Related]
13. High seroprevalence for SARS-CoV-2 among household members of essential workers detected using a dried blood spot assay.
McDade TW; McNally EM; Zelikovich AS; D'Aquila R; Mustanski B; Miller A; Vaught LA; Reiser NL; Bogdanovic E; Fallon KS; Demonbreun AR
PLoS One; 2020; 15(8):e0237833. PubMed ID: 32797108
[TBL] [Abstract][Full Text] [Related]
14. Seroprevalence of SARS-CoV-2 antibodies in social housing areas in Denmark.
Fogh K; Eriksen ARR; Hasselbalch RB; Kristensen ES; Bundgaard H; Nielsen SD; Jørgensen CS; Scharff BFSS; Erikstrup C; Sækmose SG; Holm DK; Aagaard B; Norsk J; Nielsen PB; Kristensen JH; Østergaard L; Ellermann-Eriksen S; Andersen B; Nielsen H; Johansen IS; Wiese L; Simonsen L; Fischer TK; Folke F; Lippert F; Ostrowski SR; Ethelberg S; Koch A; Vangsted AM; Krause TG; Fomsgaard A; Nielsen C; Ullum H; Skov R; Iversen K
BMC Infect Dis; 2022 Feb; 22(1):143. PubMed ID: 35144550
[TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2 seroprevalence in Portugal following the third epidemic wave: results of the second National Serological Survey (ISN2COVID-19).
Kislaya I; Gonçalves P; Gómez V; Gaio V; Roquette R; Barreto M; Sousa-Uva M; Torres AR; Santos J; Matos R; Manita C; Almeida Santos J; Soeiro S; de Sousa R; Costa I; Verdasca N; Guiomar R; Rodrigues AP;
Infect Dis (Lond); 2022 Jun; 54(6):418-424. PubMed ID: 35023439
[TBL] [Abstract][Full Text] [Related]
16. Estimated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Based on Blood Donations, July 2020-May 2021.
Jones JM; Stone M; Sulaeman H; Fink RV; Dave H; Levy ME; Di Germanio C; Green V; Notari E; Saa P; Biggerstaff BJ; Strauss D; Kessler D; Vassallo R; Reik R; Rossmann S; Destree M; Nguyen KA; Sayers M; Lough C; Bougie DW; Ritter M; Latoni G; Weales B; Sime S; Gorlin J; Brown NE; Gould CV; Berney K; Benoit TJ; Miller MJ; Freeman D; Kartik D; Fry AM; Azziz-Baumgartner E; Hall AJ; MacNeil A; Gundlapalli AV; Basavaraju SV; Gerber SI; Patton ME; Custer B; Williamson P; Simmons G; Thornburg NJ; Kleinman S; Stramer SL; Opsomer J; Busch MP
JAMA; 2021 Oct; 326(14):1400-1409. PubMed ID: 34473201
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of SARS-CoV-2 IgG antibodies in an area of northeastern Italy with a high incidence of COVID-19 cases: a population-based study.
Stefanelli P; Bella A; Fedele G; Pancheri S; Leone P; Vacca P; Neri A; Carannante A; Fazio C; Benedetti E; Fiore S; Fabiani C; Simmaco M; Santino I; Zuccali MG; Bizzarri G; Magnoni R; Benetollo PP; Merler S; Brusaferro S; Rezza G; Ferro A
Clin Microbiol Infect; 2021 Apr; 27(4):633.e1-633.e7. PubMed ID: 33253941
[TBL] [Abstract][Full Text] [Related]
18. Seroprevalence of SARS-CoV-2-specific IgG antibodies in Kashmir, India, 7 months after the first reported local COVID-19 case: results of a population-based seroprevalence survey from October to November 2020.
Khan SMS; Qurieshi MA; Haq I; Majid S; Ahmad J; Ayub T; Bhat AA; Fazili AB; Ganai AM; Jan Y; Kaul RU; Khan ZA; Masoodi MA; Mushtaq B; Nazir F; Nazir M; Raja MW; Rasool M; Asma A; Ayoub S; Aziz M; Bhat AA; Chowdri IN; Ismail S; Kawoosa MF; Khan MA; Khan MS; Kousar R; Lone AA; Nabi S; Obaid M; Qazi TB; Sabah I; Sumji IA
BMJ Open; 2021 Sep; 11(9):e053791. PubMed ID: 34556519
[TBL] [Abstract][Full Text] [Related]
19. Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.
Tang X; Sharma A; Pasic M; Brown P; Colwill K; Gelband H; Birnboim HC; Nagelkerke N; Bogoch II; Bansal A; Newcombe L; Slater J; Rodriguez PS; Huang G; Fu SH; Meh C; Wu DC; Kaul R; Langlois MA; Morawski E; Hollander A; Eliopoulos D; Aloi B; Lam T; Abe KT; Rathod B; Fazel-Zarandi M; Wang J; Iskilova M; Pasculescu A; Caldwell L; Barrios-Rodiles M; Mohammed-Ali Z; Vas N; Santhanam DR; Cho ER; Qu K; Jha S; Jha V; Suraweera W; Malhotra V; Mastali K; Wen R; Sinha S; Reid A; Gingras AC; Chakraborty P; Slutsky AS; Jha P;
JAMA Netw Open; 2022 Feb; 5(2):e2146798. PubMed ID: 35171263
[TBL] [Abstract][Full Text] [Related]
20. Seroprevalence of SARS-CoV-2 antibody among urban Iranian population: findings from the second large population-based cross-sectional study.
Zamani M; Poustchi H; Mohammadi Z; Dalvand S; Sharafkhah M; Motevalian SA; Eslami S; Emami A; Somi MH; Yazdani-Charati J; Saki N; Karami M; Najafi F; Mohebbi I; Veisi N; Hormati A; Pourfarzi F; Ghadimi R; Ansari-Moghaddam A; Sharifi H; Roshandel G; Mansour-Ghanaei F; Joukar F; Shayanrad A; Eghtesad S; Niavarani A; Delavari A; Kaveh S; Feizesani A; Markarian M; Shafighian F; Sadjadi A; Darvishian M; Malekzadeh R
BMC Public Health; 2022 May; 22(1):1031. PubMed ID: 35606743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
